| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AVTX Stock Overview
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.36 |
| 52 Week High | US$38.88 |
| 52 Week Low | US$2.42 |
| Beta | 1.42 |
| 1 Month Change | 16.52% |
| 3 Month Change | 46.35% |
| 1 Year Change | -83.88% |
| 3 Year Change | -87.99% |
| 5 Year Change | -26.78% |
| Change since IPO | -88.83% |
Recent News & Updates
Shareholder Returns
| AVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 36.7% | 1.4% | 3.6% |
| 1Y | -83.9% | -19.6% | -9.6% |
Return vs Industry: AVTX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: AVTX underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| AVTX volatility | |
|---|---|
| AVTX Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AVTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: AVTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 43 | Garry Neil | https://www.avalotx.com |
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis.
Avalo Therapeutics, Inc. Fundamentals Summary
| AVTX fundamental statistics | |
|---|---|
| Market Cap | US$50.46m |
| Earnings (TTM) | -US$71.64m |
| Revenue (TTM) | US$3.78m |
13.4x
P/S Ratio-0.7x
P/E RatioIs AVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTX income statement (TTM) | |
|---|---|
| Revenue | US$3.78m |
| Cost of Revenue | US$32.18m |
| Gross Profit | -US$28.40m |
| Other Expenses | US$43.24m |
| Earnings | -US$71.64m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.61 |
| Gross Margin | -752.40% |
| Net Profit Margin | -1,897.75% |
| Debt/Equity Ratio | -314.5% |
How did AVTX perform over the long term?
See historical performance and comparison